Silicon Valley investors fund first human cellular reprogramming trial for glaucoma

Life Biosciences launched the inaugural human study of cellular reprogramming, targeting glaucoma by delivering a gene-based therapy via eye injection and a subsequent eight-week antibiotic regimen. The first three participants reported no serious adverse events, and two showed significant vision enhancement on clinical testing. Dr. James Tsai described the findings as exciting yet early, suggesting the drug may have boosted residual retinal signaling rather than fully regenerating tissue.

Following these outcomes, a safety board authorized a tripling of the dose for upcoming patients. Company COO Michael Ringel highlighted animal research indicating the technique could address a broad spectrum of age-related diseases, though clinical proof remains pending. The trial reflects a wider push by Silicon Valley backers, including Jeff Bezos, Peter Thiel, Yuri Milner and Sam Altman, to bring longevity technologies into human medicine.